VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Bristol-Myers Squibb Company vs QUALCOMM Incorporated
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisQUALCOMM Incorporated
QCOM · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into QUALCOMM Incorporated's moat claims, evidence, and risks.
View QCOM analysisComparison highlights
- Moat score gap: QUALCOMM Incorporated leads (70 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); QUALCOMM Incorporated has 4 segments (62.8% in Handset chipsets (Snapdragon platforms)).
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; QUALCOMM Incorporated has 7 across 4.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
QUALCOMM Incorporated
Handset chipsets (Snapdragon platforms)
Smartphone application processors and cellular modem/RF platforms
Global
Smartphone OEMs
fabless semiconductor/platform supplier
62.8%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
QUALCOMM Incorporated strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
QUALCOMM Incorporated segments
Full profile >Handset chipsets (Snapdragon platforms)
Oligopoly
Automotive silicon (connectivity, digital cockpit, ADAS/AD)
Oligopoly
IoT silicon (consumer, industrial, edge networking)
Competitive
Wireless technology licensing (cellular SEPs, royalties)
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.